Mechanisms of Human Cytomegalovirus Latency

人类巨细胞病毒潜伏期的机制

• 批准号: 9075229
• 负责人: Eain A Murphy
• 金额: $ 43.75万
• 依托单位: EVRYS BIO, LLC
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9075229
• 关键词: Address; Adult; Area; Biological; Biological Factors; Biological Models; Cell Line; Cells; Cytomegalovirus; Data; Development; Disadvantaged; Disease; Early Gene Transcriptions; Environment; Equilibrium; Exhibits; FDA approved; Family; Family member; Foundations; Genetic Transcription; Genome; Goals; Health; Host Defense; Immediate-Early Genes; Immune system; Immunocompromised Host; Individual; Infection; Inflammatory; Interleukin-1; Link; Lytic; Lytic Phase; MIEP; Maintenance; Mediating; MicroRNAs; Modeling; Molecular; Monitor; Morbidity - disease rate; Myeloid Progenitor Cells; NF-kappa B; Patients; Pharmaceutical Preparations; Play; Positioning Attribute; Process; Production; Proteins; Publishing; Reporting; Role; Signal Pathway; Simplexvirus; Staging; Stimulus; System; TNF gene; Testing; Transcript; Translations; Vaccines; Viral; Viral Genome; Viral Pathogenesis; Viral Proteins; Virus; Virus Diseases; Virus Latency; Work; base; combat; cytokine; gene induction; gene repression; genetic manipulation; inhibitor/antagonist; innovation; insight; latent infection; lytic replication; mortality; new therapeutic target; novel; pathogen; promoter; reactivation from latency; research study; response; targeted treatment; transcription factor

DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) establishes lifelong latent infections in a host and reactivates with devastating consequences within immunosuppressed patients, underscoring the need to identify the conditions that dictate HCMV latency. To this end, we have developed and reported a novel HCMV latency model system utilizing Kasumi 3 cells (K3s) that recapitulates ALL the key stages of HCMV reactivation allowing us to experimentally test conditions critical for HCMV latency that were previously not possible. This proposal aims to test the hypothesis that the antagonistic relationship between miRNA-induced suppression of HCMV IE genes and cytokine-mediated induction of IE genes is a major determinant of the switch from latent to lytic infection. We base this concept on our exciting observations that cellular encoded hsa-miR-200 family members target the essential HCMV Immediate Early (IE) 2 protein. Additionally, we show that IE2 can induce viral Early (E) promoters within the context of the genome and independently of additional viral proteins, providing the first confirmation that IE2 is a key regulator of HCMV viral lytic transcription. In addition, we show that inflammatory cytokines potently initiate lytic reactivation of HCMV in our K3 cels that can be blocked by treatment with an NF-kB inhibitor. Based on these observations we favor a model (derived from published observations with Herpes Simplex Virus) wherein latency is established by chromatization of the viral genome resulting in suppression of viral transcription. However, an added level of suppression mediated by miRNA targeting of IE transcripts would suppress viral translation assuring latency maintenance. We offer the novel concept that HCMV has co-opted cellular miRNAs to additionally restrict viral reactivation. We seek to extend these studies on the mechanisms underlying HCMV latency and reactivation. In Aim 1, we will determine the biological role of cellular encoded miRNAs on restricting HCMV IE translation as well as evaluate the requirement of viral encoded miRNAs on HCMV latency. Aim 2 will address the mechanisms by which inflammatory cytokines function to reactivate HCMV as well as define the requirements of cellular transcription factors on promoting the latent to lytic switch. Completion of the aims above will contribute significantly to our knowledge on the mechanisms of viral latency and lytic reactivation. This work will lay the foundation for identifyig novel therapeutic targets for a virus that is a significant global pathogen.

描述（由申请人提供）：人巨细胞病毒（HCMV）在宿主中建立终身潜伏感染，并在免疫抑制患者中重新激活，具有破坏性后果，强调需要确定决定HCMV潜伏期的条件。为此，我们开发并报告了一种利用Kasumi 3细胞（K3s）的新型HCMV潜伏期模型系统，该系统概括了HCMV再激活的所有关键阶段，使我们能够通过实验测试HCMV潜伏期的关键条件，这在以前是不可能的。本研究旨在验证mirna诱导的HCMV IE基因抑制与细胞因子介导的IE基因诱导之间的拮抗关系是HCMV从潜伏感染转向裂解感染的主要决定因素。我们基于细胞编码hsa-miR-200家族成员靶向必要的HCMV即时早期（IE） 2蛋白的激动人心的观察结果，提出了这一概念。此外，我们发现IE2可以在基因组背景下诱导病毒早期(E)启动子，独立于其他病毒蛋白，首次证实IE2是HCMV病毒裂解转录的关键调节剂。此外，我们发现炎症细胞因子能在K3细胞中有效地启动HCMV的裂解再激活，这可以通过NF-kB抑制剂治疗来阻断。基于这些观察结果，我们倾向于一个模型（来源于发表的单纯疱疹病毒观察结果），其中潜伏期是通过病毒基因组的染色化建立的，从而抑制病毒转录。然而，miRNA靶向IE转录本介导的额外抑制水平会抑制病毒翻译，确保潜伏期维持。我们提出了新的概念，即HCMV已经选择了细胞mirna来额外限制病毒的再激活。我们寻求扩展HCMV潜伏期和再激活机制的研究。在Aim 1中，我们将确定细胞编码mirna在限制HCMV IE翻译中的生物学作用，并评估病毒编码mirna对HCMV潜伏期的需求。目的2将探讨炎症细胞因子重新激活HCMV的机制，并确定细胞转录因子在促进潜伏到裂解转换方面的要求。上述目标的完成将大大有助于我们对病毒潜伏期和裂解性再激活机制的了解。这项工作将为确定一种重要的全球病原体病毒的新治疗靶点奠定基础。